Good evening, this is Markets Desk with your closing summary.
The headline that has pharma traders talking tonight is a potential megadeal between AstraZeneca and Bristol Myers Squibb. The Financial Times reports the two giants are in active discussions about a merger that would be valued at roughly four hundred billion dollars, which would rank among the largest pharmaceutical combinations in history. Watch both names closely as this develops.
Turning to semiconductor names, GlobalFoundries has been under pressure with shares sliding below fifty dollars, and insider activity is adding texture to that story. A company director sold four thousand shares for just over two hundred thirty-two thousand dollars ahead of earnings in late July, and a separate filing shows a smaller disposition of roughly eighty-two thousand dollars days later. Neither transaction is necessarily alarming on its own, but the clustering of sales near an earnings window is the kind of signal long-term holders tend to track carefully.
And in satellite imaging, Planet Labs CFO Ashley Johnson disposed of roughly one hundred ten thousand shares at just over twenty-two dollars apiece, representing a transaction valued at two point four million dollars. Executive share sales under pre-scheduled trading plans are common, but the scale here warrants attention given where the stock has been trading.
That's the tape. Markets Desk, signing off the floor.
